Retrospective Observational Study of Nab-paclitaxel (Abraxane) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice

Trial Profile

Retrospective Observational Study of Nab-paclitaxel (Abraxane) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2016

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Adenocarcinoma; Breast cancer
  • Focus Therapeutic Use
  • Acronyms AMBER
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 28 Oct 2016 Status changed from not yet recruiting to discontinued.
    • 29 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top